Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using ²¹³Bi-Anti-CD20 Monoclonal Antibody

Keyphrases

• Rituximab 100%
• B-cell Lymphoma 100%
• 213Bi 100%
• Micrometastatic 100%
• Anti-CD20 Antibody 100%
• SCID Mouse Model 100%
• Non-Hodgkin Lymphoma 23%
• Tositumomab 23%
• Tumor 15%
• Inoculation 15%
• Radioimmunotherapy 15%
• Lymphoma Cells 15%
• Multiple Dose 7%
• Dose Effect 7%
• Survivors 7%
• In Vitro Study 7%
• Luciferase Reporter 7%
• Long-lived 7%
• Tumor Burden 7%
• High Energy 7%
• Low Energy 7%
• Her2neu 7%
• Anti-HER2 7%
• Human B Cells 7%
• Specific Antibodies 7%
• Raji 7%
• Dosing Regimen 7%
• Bioluminescence Imaging 7%
• Bioluminescent 7%
• Redosing 7%
• Radiometals 7%
• Tumor-free 7%
• Tumor Growth Delay 7%
• High Tumor Burden 7%
• Anti-CD20 Therapy 7%
• α-emitter 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse Model 100%
• SCID Mouse 100%
• Rituximab 100%
• Bismuth 213 100%
• B Cell Lymphoma 100%
• Neoplasm 35%
• Mouse 21%
• Nonhodgkin Lymphoma 21%
• Iodine-131 21%
• Yttrium 90 21%
• Tositumomab 21%
• Disease 7%
• Tumor Growth 7%
• Antibodies 7%
• Luciferase 7%
• CD20 Antibody 7%

Neuroscience

• Rituximab 100%
• B Cell 100%
• In Vivo 21%
• Tositumomab 21%
• Non-Hodgkin Lymphoma 21%
• In Vitro 14%
• Luciferase 7%
• Antibodies 7%
• CD20 7%
• HER2/neu 7%
• CD20 Antibody 7%